Sinopharm to undergo ownership reform in pilot SASAC program
By Kristine Yang
Wednesday, July 23, 2014
HONG KONG – Sinopharm Group, one of the largest biotech companies in China, is likely to undergo major structural reforms as the government kicks off a series of reforms on its state-owned enterprises (SOEs).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.